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Introduction: N-methyl-D-aspartate receptor (NMDAR) antago-
nists are used for postsurgery neuropathic pain states, but severe side 
effects limit their clinical use. Memantine, when given after surgery, 
shows contradictory results as regards neuropathic pain alleviation.
Patients (or Materials) and Methods: Memantine is administered 
in animals before or after spinal nerve ligation (SNL) to evaluate 
the antinociceptive/cognitive effects and associated molecular events 
(including phosphorylated-Tyr1472NR2B subunit). SNL animals 
received memantine or saline 4 days before (pre-emptive) or after 
surgery (postoperative) for 7 days, were tested for tactile allodynia, 
mechanical hyperalgesia, cognitive function and spinal cord molecu-
lar events, and results were compared (significance P < 0.05).
Results: Postoperative memantine had no beneficial effect on tac-
tile allodynia, mechanical hyperalgesia, or spatial memory, and 
molecular expression of NR2B subunit was significantly increased. 
Pre-emptive memantine prevented the development of mechanical 
hyperalgesia, tactile allodynia, and impairment of spatial memory; 
spinal pTyr1472NR2B was not increased.
Conclusion: Blockade of NMDAR by memantine 4 days before sur-
gery rather than postoperatively is a promising strategy in animals to 
alleviate neuropathic pain development and impairment of cognitive 
function. The pivotal role of pTyr1472NR2B must be studied further, 
and confirmation of these findings in patients would constitute a 
giant footstep in the prevention of neuropathic pain that frequently 
follows surgical procedures.
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Introduction: With > 25% of the American population experiencing 
daily pain and the number of new drugs still in the single-digit area, it 
is becoming more and more of an important health problem to come 
up with new or improved analgesis compounds. Our paper proposes 
a new approach for obtaining an efficient controlled-release system 
for the pain treatment via inovative polymeric nanoparticles by using 
an interfacial condensation method between a natural polymer, chi-
tosan (CS) and a synthetic one (poly (maleic anhydride -alt -vinyl 
acetate), (poly (MAVA).
Patients (or Materials) and Methods: Chitosan, acetone, Ibuprofen 
(IBU), hexane, and surfactants were used (Sigma Aldrich). The alter-
nant copolymer – poly (MAVA) was synthesized by radical copolym-
erization and characterized in our laboratory. The nanocapsules were 
characterized and investigated by Fourier transform infrared spec-
troscopy (FTIR), Scanning Electron Microscope (SEM), Transmission 
Electron Microscope (TEM), thermogravimetric analysis (TGA), and 
differential scanning calorimetry (DSC). In vitro IBU loading and 
release was also investigated. In vivo testing of IBU/nanocapsules 
was evaluated by hot plate test and tail flick test, behavioral tests 
that quantify the thermal nociception. Adult male Swiss mice in dif-
ferent groups of 8 mice each were intraperitoneally injected with 
one of the following formulations: 0.9% saline for a control group; 
ibuprofen for positive control group (100 mg/kg b.w.); ibuprofen-
loaded nanocapsules (MAVA-CS-9) for test group (100 mg/kg b.w. 
equivalent ibuprofen). Inhibition to pain stimuli was then calculated.
Results: Zeta potential determinations indicated a good stability of 
the nanocapsules in aqueous solutions. Scanning electron micros-
copy confirmed the nanometric dimensions and the spherical shape 
of the nanocapsules. The thermal properties achieved by DSC and 
ATG showed the nanocapsules’ good thermal stability. In addition, 
these systems present a good swelling capacity, which is influenced by 
the reaction parameters taken into account in this study. The drug-
loading and -release capacity (studied for ibuprofen sodium salt used 
as water-soluble drug) is controlled by the diffusion speed through 
the polymeric membrane and is influenced by the swelling degree. 
Although ibuprofen alone has a half-life of 1 to 3 hours, and previ-
ous studies showed an analgesic improvement of their nanoparticle 
formulations in the 1- to 2-hour range, our system has a time interval 
of 2 to 6 hours of analgesic efficacy, an increase of up to 6 times the 
reference ibuprofen formulation.
Conclusion: We have proved the possibility of a sustained-release 
system for central pain inhibition (from 2 to 24 hours) versus 0 to 
2 hours ibuprofen control. Future variations in the ibuprofen load 
of the nanocapsules could yield potentially significant commercial 
applications with improved efficacy and safety profiles.
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Introduction: It known that bile acids improve the absorption, bio-
availability, and pharmacodynamic characteristics of some drugs. 
Because morphine analgesia is produced by activation of opioid 
receptors within the central nervous system at both spinal and 
supraspinal levels, and because morphine molecule contains 3 polar 
groups, and as such is hard to transfer through the blood-brain bar-
rier, the aim of the study was to examine the potential influence 
of bile acids derivates, namely sodium salt of monoketocholic acid 
(MKH-Na) and methyl ester of monoketocholic acid (MKH-Me) on 
analgesic effect of morphine.
Patients (or Materials) and Methods: White male mice of NMRI-
Haan strain, with body weight of 20 to 24 g, were used in this study. 
Analgesic effect of morphine was estimated by the hot plate method. 
Analgesic effect of morphine (2 mg/kg) (administered by subcutane-
ous and intramuscular route of administration) with and without 
pretreatment with MKH-Na (4 mg/kg) and MKH-Me (4 mg/kg) was 
measured.
Results: Administration of MKH-Me before subcutaneous admin-
istration of morphine increased the morphine analgesic effect, but 
the increase was not statistically significant. At the same time the 
administration of MKH-Na did not affected morphine analgesic 
effect. Analgesic effect of morphine was increased when morphine 
